San Francisco, CA, United States of America

Rosa Barreira Da Silva

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Institut Pasteur, National Institute of Health and Medical Research. Active years: 2021-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rosa Barreira Da Silva. Retrieved from https://idiyas.com/inventor/rosa-barreira-da-silva

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2021-2024

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Rosa Barreira Da Silva: Innovator in Immunotherapy

Introduction

Rosa Barreira Da Silva is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of immunotherapy, particularly through her innovative research and patents. With a total of 3 patents, her work focuses on enhancing tumor immunity and improving therapeutic strategies.

Latest Patents

One of her latest patents is titled "Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy." This groundbreaking research demonstrates that the success of anti-tumor immune responses relies on effector T cells infiltrating solid tumors, a process guided by chemokines. The study reveals that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhances tumor rejection by preserving biologically active CXCL10 and increasing lymphocyte trafficking into the tumor. Furthermore, DPP4 inhibition improves adjuvant-based immunotherapy, adoptive T cell transfer, and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors as a strategy to enhance tumor immunotherapy.

Career Highlights

Rosa has worked with esteemed organizations such as Institut Pasteur and the Institut National de la Santé et de la Recherche Médicale. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to significant advancements in medical research.

Collaborations

Rosa has collaborated with notable professionals, including Matthew Albert, to further her research and innovations in immunotherapy.

Conclusion

Rosa Barreira Da Silva is a trailblazer in the field of immunotherapy, with her innovative patents paving the way for enhanced cancer treatment strategies. Her work continues to inspire advancements in medical research and therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…